Drugs / gemcitabine elaidate
gemcitabine elaidate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01641575 | Jul 2012 → May 2013 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00778128 | Oct 2008 → Apr 2010 | cancer | Clavis Pharma | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01233375 | Apr 2011 → Mar 2013 | pancreatic adenocarcinoma | Clovis Oncology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01124786 | May 2010 → Nov 2012 | pancreatic adenocarcinoma | Clovis Oncology, Inc. | Completed | Missed primary |
| Phase 2 | NCT00913198 | Apr 2009 → Jun 2011 | pancreatic adenocarcinoma | Clavis Pharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01392976 Comparator | Apr → Oct 2011 | neoplasm | Clovis Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gemcitabine elaidate | “These data support the hypothesis that patients expressing low levels of hENT1 will derive minimal benefit from gemcitabine, but will receive benefit from CO-1.01 (gemcitabine...” NCT01392976 ↗1“but will receive benefit from CO-1.01 (gemcitabine elaidate) which enters tumor cells in a hENT1-independent fashion.” NCT01124786 ↗ |
| Known as | CO-1.01 | “These data support the hypothesis that patients expressing low levels of hENT1 will derive minimal benefit from gemcitabine, but will receive benefit from CO-1.01 (gemcitabine...” NCT01392976 ↗4“Furthermore, the PK profiles of CO-1.01 and gemcitabine are dissimilar and this may confer additional clinical benefit on CO1.01.” NCT01233375 ↗ |
| Known as | CP-4126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00913198 ↗ |
| Known as | Elaidate de gemcitabine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039516 ↗ |
| Known as | Elaidato de gemcitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039516 ↗ |
| Modality | Small molecule | “CP-4126 is a gemcitabine (2',2'-difluorodeoxycytidine; dFdC) 5' elaidic acid ester.” PMID 23345000 ↗ Jan 2013 |
| Route | Oral | “Step 1: Dose escalation oral CP-4126 until maximum tolerated dose.” NCT00778128 ↗ |